STK32C

Across TCGA pan-cancer cohorts, STK32C Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated STK32C data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher STK32C Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated STK32C expression acts as an unfavorable survival marker.

OV, BLCA, and UCEC are the cancer types where STK32C Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	II,III,IV	0.223	0.541	.041	18	view →
BLCA	DFS	Median	All	0.132	0.626	.006	18	view →
UCEC	OS	Median	IV	0.225	0.772	<.001	12	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
SKCM	OS	Median	III,IV	0.345	0.707	.041	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

STK32C–OV (DFS)

Open the OV breakdown →